Fayez Sarofim & Co
CRL icon

Fayez Sarofim & Co’s Charles River Laboratories CRL Stock Holding History

Fayez Sarofim & Co’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-612
Closed -$231K – 323
2021
Q4 		$231K Buy
+612
New +$238K ﹤0.01% 320
2021
Q3 		– Sell
-1,607
Closed -$594K – 312
2021
Q2 		$594K Buy
+1,607
New +$537K ﹤0.01% 242

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fayez Sarofim & Co's CRL Position: Q1 2022 in Review

Fayez Sarofim & Co sold out of Charles River Laboratories (CRL) in Q1 2022, closing a stake of 612 shares — an estimated $231K sold.

Fayez Sarofim & Co first reported a position in CRL in Q2 2021 and held it in 2 quarters. The position peaked at $594K in Q2 2021. 644 funds tracked by Wall St. Rank hold CRL as of Q1 2022.

  • Fayez Sarofim & Co reported no remaining Charles River Laboratories position as of Q1 2022 after selling out during the quarter.
  • Fayez Sarofim & Co sold 612 Charles River Laboratories shares in Q1 2022, an estimated $231K.
  • Fayez Sarofim & Co first reported a position in Charles River Laboratories in Q2 2021 and held it in 2 quarters.
  • Fayez Sarofim & Co's Charles River Laboratories position peaked at $594K in Q2 2021.
  • 644 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2022.

Based on Fayez Sarofim & Co's 13F filing for Q1 2022, filed 16 May 2022.